Polish hospital records reveal Real-World impact of Immuno-Chemo combo for lung cancer
NCT ID NCT07526961
First seen Apr 19, 2026 · Last updated Apr 28, 2026 · Updated 1 time
Summary
This study looked back at medical records of 240 adults in Poland with advanced non-small cell lung cancer who received a combination of two immunotherapy drugs (nivolumab and ipilimumab) plus chemotherapy as their first treatment. Researchers wanted to see how patients responded in everyday hospital care, not just in strict clinical trials. The goal is to understand real-world treatment patterns and outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Wielkopolska Center of Pulmonology and Thoracic Surgery of Eugenia and Janusz Zeyland
Poznan, Poland
Conditions
Explore the condition pages connected to this study.